the full sample. The MEMS group reported strong satisfaction with the text-messages. Recruitment has been completed, and analyses from the full sample will be ready to present at the meeting. Discussion: Initial results indicate that MEMS is acceptable and may successfully improve motivation in people with schizophrenia-spectrum disorders. However, additional analyses with the full sample are needed to more rigorously test the feasibility and effectiveness of MEMS. (Green, 1993; Green et al, 2000; Heaton et al., 2001; Heinrichs, 1998). While pharmacological treatment is known to have a limited effect on impaired cognition in schizophrenia (Marder, 2006; Rund and Borg, 1999; Elie et al., 2010), a majority of literature has concluded that cognitive remediation(CR) produces small to moderate improvements (McGurk et al., 2007; Wykes et al., 2011). As the smartphone user population continues to increase, the effectiveness of CR based on mobile devices have started to be studied. While CR is effective in improving cognitive deficit, treatment adherence and engagement of participants in the real world setting is known to be poor compared to laboratory setting. Thus, in the current randomized controlled study, we aimed to investigate whether motivational intervention would enhance motivation, treatment adherence and neurocognitive function of individuals with schizophrenia. Methods: All subjects participated in a group-based CR using mobile application (mCR) twice a week for five weeks, and were given opportunity to practice voluntarily outside the treatment sessions. While CR only group participated in usual CR with Q&A sessions, experimental group participated CR sessions integrated with motivational intervention. For motivational enhancement (ME), we employed principles (e.g., goal setting, linking of CR with life goals, etc) of the bridging group (Medalia, Revheim, & Herlands, 2009) along with key aspects of motivational interviewing (e.g., open end questions, affirmation, reflect, and summary). We hypothesized that compared to CR only group, CR+ME group would show higher levels of intrinsic motivation, attendance rate and extra voluntary training hours, and greater improvement in cognitive functions.
S52. WORKING MECHANISMS OF VIRTUAL
Background: Recently, the efficacy of a novel virtual reality based cognitive behavior therapy (VR-CBT) for paranoia was demonstrated. Cognitive biases, cognitive limitations, negative schematic beliefs and safety behavior have been associated with paranoid ideations and delusions. It is unknown whether VR-CBT affects these associated factors, and how changes in these factors relate to changes in paranoid ideation. Methods: In this multi-center randomized controlled trial patients with a psychotic disorder and paranoia were randomized to VR-CBT (n = 58) or treatment as usual (TAU; n = 58). VR-CBT consisted of maximally sixteen 60-minute individual therapy sessions. Paranoia, safety behavior, schematic beliefs, cognitive biases and limitations were assessed at baseline, post-treatment (at three months) and follow-up (at six months). Mixed model analyses were conducted to study treatment effects. Mediation analyses were performed to explore putative working mechanisms by which VR-CBT reduced paranoia. 
Zanjan University of Medical Sciences
Background: Cognitive impairment is the most important feature of schizophrenia that leads to severe social and functional disability. Improving neurocognitive physiopathologic aspect of schizophrenia is a current challenge to identify the pathway to develop goal directed clinical interventions in practice. In the current study we investigated the effect of raloxifine as a selective estrogen modulator and isradipine as a voltage gated L type calcium channel blocker on the enhancement of schizophrenic patients' cognitive deficits. Methods: We designed a double blind randomized, parallel, placebo controlled clinical trials. 60 patients with schizophrenia randomized in 3 specific groups. The first group received isradipine 5 mg, the second raloxifine 60 mg and the third placebo for 6 consequent weeks, in the same shape capsules, 2 times a day, alongside treatment with the conventional antipsychotics. The initial and final lab tests, ECG, as well as cognitive tests in specific domains such as attention, processing speed, executive function and verbal memory were carried out. Results: Our findings, revealed a remarkable association between adjunctive treatment of raloxifine in verbal memory deficits. moreover, isradipine treatment indicated significant improvement relative to placebo in verbal memory as well as attention dysfunction in some variables of the Stroop test. However, no effect was observed in processing speed and executive function deficits. Discussion: The study provides the first evidence to our knowledge, which isradipine as a novel therapy was associated with improvement in verbal memory and attention, both related to hippocampal and cerebellar activity. Overall, further investigation is necessary to determine the various ways of the both drugs performance in the brain. Background: The inability to achieve full compliance with drug treatment during the post-discharge period with exacerbations in the illness in patients with schizophrenia and other psychotic disorders is a major problem for the patients themselves, their families, and the healthcare staff in psychiatry.
S54. THE ROLE OF THE CLINICAL PHARMACIST

Methods:
In this prospective study, it was aimed to evaluate whether the written and verbal drug education (drug color and shape, interactions, side effects, etc.) given by the clinical pharmacist during the discharge period had an effect on drug compliance. Between 1st September 2016 and 12th June 2017, 40 patients diagnosed with schizophrenia, schizoaffective disorder, schizotypal personality disorder or acute schizophrenia-like psychotic disorder according to ICD-10 diagnostic criteria who were admitted to Hacettepe University Faculty of Medicine, Department of Psychiatry Inpatient Service, were involved in this study. A number of scales were used to evaluate the severity of illness, drug side effects and drug compliance respectively; PANSS; UKU, SAS, BARS, AIMS; MARS and ROMI. It has been emphasized during discharge to the patients by the clinical pharmacist that how important administering the prescribed medicines regularly and as directed. Six to 8 weeks after discharge, the patients were invited to be reevaluated using the scales applied during admission.
Results: There was a statistically significant increase in compliance with treatment as quantitatively assessed by the MARS after drug education (p<0.001).
There was no significant correlation between compliance and gender, age, tobacco/alcohol use or marital status. At the same time, a significant correlation between severity of akathisia obtained through BARS and a decrease in MARS scores representing the level of compliance was observed (r: -0.367; p<0.05). A decrease in the baseline MARS score was related to an increase in the total number of hospitalizations (r: -0.325; p<0.05) and the number of psychotropic drugs used (r: -0.316; p<0.05). When the factors that may affect compliance were examined by multiple regression analysis, akathisia was found to have the highest impact on compliance (ß: -0.389, r2: -0.002, F: 0.750). Discussion: These results support the literature in terms of the importance of the impact of side effects on compliance. As a result of the study, it was seen that drug counseling services given by clinical pharmacists can effectively be employed in psychiatric care, for the rational use of medicines. It appears that it is necessary to take advantage of drug counseling on drug use and to develop strategies to improve drug compliance in psychiatry. , Hema Nawani
S55. MECHANISTIC BASIS OF FRONTO-
